Canadian drug companies agree to divulge how much they pay doctors, health groups

Amid ongoing controversy over the fees pharmaceutical companies pay doctors, 10 Canadian-based firms have agreed to divulge how much cash they hand over to physicians and health organizations every year. They say the voluntary program should make the financial ties between pharma and medicine more visible – and help “neutralize” charges of conflict of interest. The firms plan to start publishing statistics on their overall payments to health professionals next year, though will stop short of releasing figures for individual physicians, as now required in the United States. “To us, building trust is fundamental – to actually meet or exceed …

Read More »

TABAC et Transparence : Les dépenses de lobbying dévoilées au grand jour

La Transparence au cœur des relations d’influence de l’industrie du tabac. Focus sur les dispositions de la loi de modernisation de notre système de santé votée le 17 décembre 2015 à l’Assemblée nationale. Le législateur défini largement la liste des acteurs désormais concernés par le dispositif de transparence : – Les fabricants de produits du tabac[1] ; – Les importateurs de produits du tabac ; – Les distributeurs de produits du tabac ; – Les entreprises, les organisations professionnelles et associations les représentant. Ainsi, toutes les entités impliquées dans le secteur du tabac, que ce soit dans un but promotionnel, …

Read More »

GSK confident over end to doctor payments

GlaxoSmithKline has become the first big drugmaker to stop paying doctors to promote its products in response to mounting pressure on the pharmaceuticals industry over conflicts of interest with medical professionals. The UK group will no longer pay medics anywhere in the world to make presentations on its behalf at medical seminars — setting it apart from rivals which still routinely hire senior doctors to educate their peers about drug brands. The new policy, which came into force this week after two years of planning, marks the latest step by GSK to clean up its reputation after a damaging corruption …

Read More »

Food companies and conflicts of interest | Five more sponsored studies with expected results

In case you haven’t been following this saga by Marion Nestle, she’s been collecting studies funded by food companies since last March and posting them according to whether the results do or do not favor the sponsor’s interests. The point of this exercise is to demonstrate that sponsored studies are far more likely to favor the interests of the sponsor than are studies funded by government agencies or foundations, and to argue for more independent funding of food and nutrition research (see her recent Viewpoint on this topic in JAMA Internal Medicine). Here are five more examples by Marion Nestle

Read More »

Australia : New financial transparency arrangements between doctors and drug companies

Australian Code of Disclosure, Transparency, Sunshine Act

In early 2015 the Australian Consumer and Competition Commission (ACCC) authorized a new Code of Conduct for Medicines Australia (representing the larger drug companies in Australia but not generic makers). This 18th Code Edition now includes making public all payments to doctors who speak at drug company events, payments for work on company advisory boards, and the monetary equivalent of gifts from companies to doctors for overseas and local travel, accommodation, conference registration fees and other forms of hospitality. This move to greater transparency started back in 2009 and culminated this year with the adoption of many of the elements …

Read More »